Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for AUROPHARMA
Revenue projections for AUROPHARMA

AUROPHARMA is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 1.81300
forwardPE 16.14220
debtToEquity 21.31000
earningsGrowth 0.01900
revenueGrowth 0.05600
grossMargins 0.59919
operatingMargins 0.14936
trailingEps 60.36000
forwardEps 88.53811

AUROPHARMA's current ratio being 1.813 suggests the company will have no issues paying off its short-term debt. With sufficient cash reserves and current assets, AUROPHARMA can easily cover its immediate liabilities, reflecting solid financial health.
AUROPHARMA's Forward PE is well-positioned, indicating the stock price is favorable compared to its earnings. This suggests the stock is not overpriced and offers room for growth, making it an attractive option for investors looking for future value appreciation.
Aurobindo Pharma Limited's low Debt-to-Equity ratio indicates that the company isn't over-leveraged, suggesting it maintains a healthy balance between debt and equity. This lowers financial risk and points to a stable financial foundation, reassuring investors of the company's financial health.
Aurobindo Pharma Limited's negative gross and operating margins signal that the company is not profitable, struggling to cover costs associated with production and operations. This could be a red flag for its financial performance moving forward.
AUROPHARMA's forward EPS is higher than its trailing EPS, suggesting the company is expected to see an increase in profitability this year. This points to positive growth, indicating that AUROPHARMA is projected to improve its financial performance compared to the previous year.

Price projections:

Price projections for AUROPHARMA
Price projections for AUROPHARMA

The price of AUROPHARMA has consistently remained close to the lower end of price projections. This trend may reflect uncertainty in the market regarding the company's ability to deliver on growth expectations.

Recommendation changes over time:

Recommendations trend for AUROPHARMA
Recommendations trend for AUROPHARMA


The analysts' recent buy bias for Aurobindo Pharma Limited indicates strong confidence in the stock's future performance. This could encourage more investors to view Aurobindo Pharma Limited as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.